Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for Tyrvaya Nasal Spray

Oyster Point Pharma announced it has launched a patient support program called TEAMTyrvaya where eligible¹ patients can pay as little as $0 for Tyrvaya (varenicline solution) Nasal Spray 0.03 mg. The FDA, approved Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease on October 15, 2021. Tyrvaya Nasal Spray is a highly selective cholinergic agonist delivered twice daily as an aqueous nasal spray into each nostril to activate basal tear production. Nasal spray administration provides a new way to treat dry eye disease without administering medication onto an already irritated ocular surface. In addition, nasal delivery may allow some patients who have difficulty administering topical eye drops to administer independently their prescribed dry eye disease therapy.

"Oyster Point Pharma is committed to helping people with dry eye disease have access to the treatments they need and therefore have established comprehensive patient affordability and access programs, including a co-pay savings offer to allow eligible patients with commercial insurance to pay as little as $0 for Tyrvaya Nasal Spray," John Snisarenko, Chief Commercial Officer of Oyster Point Pharma, said in a company news release. "We are working closely with the eye care provider community to share these resources with their constituents and help people with dry eye disease have access to the resources they need."

For more information on the TEAMTyrvaya patient support program and how to enroll, visit www.Tyrvaya-Pro.com.

TYRVAYA Nasal Spray will be available with a prescription in cartons containing two multidose nasal spray bottles. Each nasal spray bottle covers treatment for 15 days, administered twice daily into each nostril. Samples that provide 15 days of treatment will also be made available to eye care providers.

References:

1. Limitations apply. Eligible, commercially insured patients with coverage for Tyrvaya™ pay as little as $0, up to a savings maximum of $275 for each 30-day prescription. Patient is responsible for any out-of-pocket costs once monthly savings limit is reached. Eligible, commercially insured patients awaiting a coverage decision from their insurance plan pay $10 for each 30-day prescription as a bridge to coverage. The bridge to coverage $10 offer expires 07/31/2022. Offer not valid under Medicare, Medicaid, or any other federal or state program. Offer not valid for non-insured/cash-paying patients. Oyster Point reserves the right to change or discontinue this offer at any time, without notice. See complete Terms & Conditions for details.
    
2. Market-Scope. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. October 2020.
    
3. Tsubota K, Pflugfelder S, Liu Z, Baudouin C. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020;21(23):1-24. https://pubmed.ncbi.nlm.nih.gov/33291796/
    
4. Willcox, M. D., Argüeso, P., Georgiev, G. A., Holopainen, J. M., Laurie, G. W., Millar, T. J., ... & Jones, L. (2017). TFOS DEWS II tear film report. The ocular surface, 15(3), 366-403.